generic drugs

  1. 60 Minutes – Generic Drug Pricing

    60 Minutes is researching a story about generic drug price increases and allegations that prices went up due to price fixing. We are looking to speak confidentially with sales and marketing representatives in the generic drug industry with any knowledge of this. You can reach Ali Rawaf by email...
  2. 60 Minutes – Generic Drug Pricing

    60 Minutes is researching a story about generic drug price increases and allegations that prices went up due to price fixing. We are looking to speak confidentially with sales and marketing representatives in the generic drug industry with any knowledge of this. You can reach Ali Rawaf by email...
  3. 60 Minutes – Generic Drug Pricing

    60 Minutes is researching a story about generic drug price increases and allegations that prices went up due to price fixing. We are looking to speak confidentially with sales and marketing representatives in the generic drug industry with any knowledge of this. You can reach Ali Rawaf by...
  4. 60 Minutes – Generic Drug Pricing

    60 Minutes is researching a story about generic drug price increases and allegations that prices went up due to price fixing. We are looking to speak confidentially with sales and marketing representatives in the generic drug industry with any knowledge of this. You can reach Ali Rawaf by...
  5. Teva Pharma gets FDA approval

    Teva pharma receives a booster shot with FDA's approval for its generic version of EpiPen and EpiPen Jr. This will be a real threat to Mylan. Also, Teva and Regeneron announce positive Phase 3 Fasinumab results in patients with chronic pain from osteoarthritis...
  6. pillow

    Teva pharma receives a booster shot with FDA's approval for its generic version of EpiPen and EpiPen Jr. This will end the monopoly of Mylan. Also, Teva and Regeneron announce positive Phase 3 Fasinumab results in patients with chronic pain from osteoarthritis...
  7. Rite Aid narrows earnings outlooks

    Shares of the drug retailer Rite Aid Corp (RAD) tanked on Monday after the company narrowed its fiscal 2019 earnings outlook.